The age-related macular degeneration market is growing as the global population ages and demand rises for treatments that help manage vision-threatening retinal conditions. The market was valued at USD 15.07 billion in 2024 and is projected to reach USD 19.8 billion by 2032, expanding at a CAGR of 3.48%. 1103

Age-related macular degeneration, or AMD, affects the macula—the central part of the retina responsible for detailed vision. AMD is a major cause of vision loss in older adults and can make tasks such as reading, driving, recognizing faces, and seeing fine details more difficult.

Anti-vascular endothelial growth factor, or anti-VEGF, therapy is the leading treatment segment because of its established role in treating wet AMD. These medicines are administered through intravitreal injections by qualified eye-care specialists. Laser therapy, photodynamic therapy, intraocular corticosteroids, and nutritional support products also form part of the broader market.

Dry AMD represents most cases, while wet AMD typically requires more active treatment because of abnormal blood vessel growth. Geographic atrophy and choroidal neovascularization are important disease-stage segments that are driving research into new therapies.

Advanced diagnostic devices are supporting earlier detection and better monitoring. Optical coherence tomography systems, fundus cameras, visual-field analyzers, and AI-enabled imaging tools can help ophthalmologists track retinal changes and personalize treatment follow-up.

Hospitals, ophthalmology practices, specialized vision centers, and research institutes are major end users. North America leads the market because of its advanced eye-care infrastructure and high adoption of specialized treatments. Asia-Pacific is expected to grow as awareness, diagnostic access, and geriatric healthcare services expand.

Read more: Age-Related Macular Degeneration Market 1103

FAQs

Q1. What is age-related macular degeneration?
AMD is an eye condition affecting the macula, which is responsible for central, detailed vision.

Q2. Which treatment segment leads the AMD market?
Anti-VEGF therapy leads because it is widely used in managing wet AMD under specialist supervision.

Tags: age-related macular degeneration market, AMD treatment, anti-VEGF therapy, retinal disease, ophthalmology care